Sign In
Buy SGMT
$6.86
+0.0700 (+1.03%)
At Close: Jun 03, 2026
Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference
07:00am, Thursday, 20'th Nov 2025
SAN MATEO, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic
Sagimet Biosciences Advances Denifanstat: Q3 Earnings And Upcoming Catalysts
05:48am, Tuesday, 18'th Nov 2025
Sagimet Biosciences reported a Q3 GAAP EPS loss of -$0.40, missing estimates, but maintains strong momentum with Denifanstat's clinical progress. SGMT's cash position remains robust at $125.5 million,
Sagimet Biosciences Presents Two Denifanstat Posters at AASLD—The Liver Meeting® 2025
07:00am, Monday, 10'th Nov 2025
A secondary analysis of FASCINATE-2 Phase 2 trial demonstrated denifanstat improved fibrosis, inflammation and steatosis in advanced qF4 MASH patients as measured by artificial intelligence (AI) digit
Denifanstat met all primary and secondary endpoints versus placebo and was generally well tolerated in a Phase 3 clinical trial in acne in China conducted by license partner Ascletis Ascletis announce
All You Need to Know About Sagimet Biosciences Inc. (SGMT) Rating Upgrade to Strong Buy
01:01pm, Wednesday, 15'th Oct 2025
Sagimet Biosciences Inc. (SGMT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences
07:00am, Tuesday, 14'th Oct 2025
SAN MATEO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional
Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration
06:00am, Tuesday, 14'th Oct 2025
- Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulgaris compared with placebo in a Phase III ra
Denifanstat Advances: Sagimet Builds Momentum Toward 2026 Readouts
09:30am, Tuesday, 07'th Oct 2025
Sagimet Biosciences (SGMT) is well-positioned financially, with $135 million in cash and minimal debt, supporting operations through early 2028. SGMT's lead asset, denifanstat, is advancing in combina
Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025
07:00am, Tuesday, 07'th Oct 2025
SAN MATEO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic
Denifanstat met all primary and secondary endpoints versus placebo Denifanstat was generally well tolerated Sagimet initiated first-in-human Phase 1 clinical trial of a second FASN inhibitor, TVB-3567
Here's Why Sagimet Biosciences Inc. (SGMT) is Poised for a Turnaround After Losing 15.8% in 4 Weeks
10:35am, Tuesday, 16'th Sep 2025
The heavy selling pressure might have exhausted for Sagimet Biosciences Inc. (SGMT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall S
Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit
07:00am, Wednesday, 10'th Sep 2025
SAN MATEO, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional
Sagimet Biosciences Inc. (SGMT) Presents At Cantor Global Healthcare Conference 2025 Transcript
10:05pm, Sunday, 07'th Sep 2025
Sagimet Biosciences Inc. (NASDAQ:SGMT ) Cantor Global Healthcare Conference 2025 September 3, 2025 1:35 PM EDT Company Participants David Happel - CEO, President & Director Eduardo Martins - Chief Med
Sagimet Gains Momentum As FDA Eases Path For MASH Drug Development
11:19am, Friday, 29'th Aug 2025
Sagimet Biosciences offers a unique play in MASH with Denifanstat, a FASN inhibitor showing both fat reduction and fibrosis regression in Phase 2b. The FDA's acceptance of non-invasive trial endpoints
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
07:00am, Tuesday, 26'th Aug 2025
SAN MATEO, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metaboli
